Professor Lim currently holds joint appointments at both the Departments of Bioengineering and Mechanical Engineering at the National University of Singapore (NUS). He is also a Principal Investigator at the Mechanobiology Institute as well as a Faculty Fellow of the Singapore-MIT Alliance Center for Science & Technology. Professor Lim heads the Nano Biomechanics Lab which conducts basic and applied research in the mechanobiology of human diseases as well as the development of microfluidic biochips for the detection and diagnosis of cancer.
Prof. Lim has published more than 200 peer-reviewed journal papers (including over 30 invited/review articles and 12 ISI highly cited papers), 20 book chapters and delivered more than 200 plenary/keynote/invited talks. He is currently on the editorial boards of 11 international journals. Prof. Lim is also a Council Member of the World Council for Biomechanics. He has co-founded 3 start-ups that exploit inventions that he has developed in his lab.
Prof. Lim and his team have won several research awards and honors including the Wall Street Journal Asian Innovation Award (Gold) 2012, Credit Suisse Technopreneur of the Year Award 2012, TechVenture Most Disruptive Innovation Award 2012, Asian Entrepreneurship Award (First Prize) 2012, President’s Technology Award 2011, Faculty Research Award 2011, IES Prestigious Engineering Achievement Award 2010, Tan Kah Kee Young Inventor’s Award 2009, highly cited author award as well as Best Paper and Best Poster awards in international conferences. His research was cited by the MIT Technology Review magazine as one of the top ten emerging technologies of 2006 that will “have a significant impact on business, medicine or culture”.
Jonathan Liau joined the Clearbridge Health Limited Group as Chief Commercial Officer in August 2017 and is responsible for overseeing the commercial strategy and development of the Group.
From June 2004 to October 2004, he was a process engineer with Amigo Pharma Consulting Pte. Ltd. where he was responsible for the design of process engineering solutions for pharmaceutical and biopharmaceutical projects. From 2004 to 2013, he was with Cordlife Services (S) Pte. Ltd.(now known as Life Corporation Services (S) Pte. Ltd.), where his last held position was chief operating officer and was responsible for the overall operations of the company.
From 2013 to 2016, he was a senior director of corporate development at Cordlife Group Limited, a company listed on the SGX-ST. He was responsible for corporate development, new products and general management responsibilities in several of the group’s subsidiaries.
From 2016 to 2017, he was a vice president (investments) at EDBI Pte. Ltd., the corporate investment arm of the Singapore Economic Development Board, where he led investments and oversaw portfolio management in the medical technology and biopharmaceutical fields.
Jonathan Liau graduated with a Master of Biochemical Engineering with Bioprocess Management from the University College London in 2004 and a Master of Business Administration from the University of Chicago in 2013.
Professor Xie is currently Dean of the Holistic Integrative Oncology Institutes, Director of the Integrative Cancer Center of Chinese and Western Medicine, Dean of the Holistic Integrative Pharmacy Institutes, Director of the Key Laboratory of Elemene Class Anti-cancer Chinese Medicine of Zhejiang Province, and Director of the Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou Normal University.
Prof. Xie was honoured with first class of the Science and Technology Progress Award of Ministry of Education in 2008, first class of the Science and Technology Award of China Society of Integrated Traditional Chinese and Western Medicine in 2009, second class of the National Science and Technology Progress Award in 2012, the China Outstanding Invention Patent Award in 2013, the Wu Jieping Medical Innovation Award in 2014, the Science and Technology Innovation Award of Ho Leung Ho Lee in 2016, and the Special Contribution Award for Science and Technology Innovation of Hangzhou city in 2017. He also obtained a fund from the Key Program of National Natural Science Foundation in 2017.
Prof. Xie innovatively proposed a new concept for the development of drugs based on the theory of integrated Chinese and Western medicine and “molecular compatibility”. Under the guidance of the theory, he led the team to discover the anti-cancer natural active ingredient of Elemene with high efficiency and low toxicity from Wenyujin which is one of the “Zhebawei” medicinal herbs, pioneered the application of liposomal targeted drug delivery system to the new drug development of Elemene, successfully developed new anti-cancer drugs with multiple targets and “two-way anticancer” effects including Elemene injection (liposomes) and Elemene oral emulsion (liposomes), and set a precedent for the treatment of cancer by small molecule terpenoids.
Ali, Scientific and Technical Advisor of Clearbridge Biomedics is the inventor of the ‘Dean Flow Fractionation’ cell separation concept. He leads the design and development of our ClearCell® line of products and CTChips®. Inventor on 4 granted patents and author of over 30 peer-reviewed scientific publications, Ali’s interests lie in developing technologies and products, building teams, and taking a concept from prototype to commercial launch and revenue.
Ali received his MS (2006) and PhD (2009) in Electrical Engineering from the University of Cincinnati, USA. Following his degree, he held Associate Scientist position at Massachusetts Institute of Technology (MIT), USA. Before joining Clearbridge, Ali worked as a Research Scientist in the newly formed Biosystems and Micromechanics (BioSyM) group at the Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore.